CAR-T细胞的临床研究进展

doi:10.3969/j.issn.1671-7171.2018.01.028

摘要
图/表
参考文献
相关文章 (15)

[1] Enblad G,Karlsson H,Loskog AS.CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma[J].Hum Gene Ther,2015,26 (8): 498-505.
[2] Dotti G,Gottschalk S,Savoldo B,et al.Design and development of therapies using chimeric antigen receptor-expressing T cells[J].Immunol Rev,2014,257 (1): 107-126.
[3] Wang X,Riviere I.Clinical manufacturing of CAR T cells: foundation of a promising therapy[J].Mol Ther Oncolytics,2016,3: 16015.
[4] Depoil D,Fleire S,Treanor BL,et al.CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand[J].Nat Immunol,2008,9 (1): 63-72.
[5] Miller BC,Maus MV.CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies[J].Oncol Res Treat,2015,38 (12): 683-690.
[6] Boulassel MR,Galal A.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation[J].Sultan Qaboos Univ Med J,2012,12 (3): 273-285.
[7] Nabhan C,Rosen ST.Chronic lymphocytic leukemia: a clinical review[J].JAMA,2014,312 (21): 2265-2276.
[8] Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365 (8): 725-733.
[9] Kalos M,Levine BL,Porter DL,et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J].Sci Transl Med,2011,3 (95): 95ra73.
[10] Porter DL,Hwang WT,Frey NV,et al.Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J].Sci Transl Med,2015,7 (303): 303ra139.
[11] Brentjens R,Yeh R,Bernal Y,et al.Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial[J].Mol Ther,2010,18 (4): 666-668.
[12] Holzinger A,Barden M,Abken H.The growing world of CAR T cell trials: a systematic review[J].Cancer Immunol Immunother,2016,65 (12): 1433-1450.
[13] Moorman AV,Harrison CJ,Buck GA,et al.Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial[J].Blood,2007,109 (8): 3189-3197.
[14] Kochenderfer JN,Wilson WH,Janik JE,et al.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J].Blood,2010,116 (20): 4099-4102.
[15] Brentjens RJ,Davila ML,Riviere I,et al.CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia[J].Sci Transl Med,2013,5 (177): 177ra138.
[16] Davila ML,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med,2014,6 (224): 224ra225.
[17] Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368 (16): 1509-1518.
[18] Maude SL,Frey N,Shaw PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371 (16): 1507-1517.
[19] Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J].Lancet,2015,385 (9967): 517-528.
[20] Kochenderfer JN,Dudley ME,Carpenter RO,et al.Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation[J].Blood,2013,122 (25): 4129-4139.
[21] Wang X,Popplewell LL,Wagner JR,et al.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL[J].Blood,2016,127 (24): 2980-2990.
[22] Stephen JS JS,Sunita N,David LP,Elise AC,Yolanda M,Simon FL,Joseph JM,Anne C,Gaurav S.Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19⁺ lymphomas[J].Blood,2014,124: 3087-3087.
[23] Zhang H,Ye ZL,Yuan ZG,et al.New Strategies for the Treatment of Solid Tumors with CAR-T Cells[J].Int J Biol Sci,2016,12 (6): 718-729.
[24] Louis CU,Savoldo B,Dotti G,et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118 (23): 6050-6056.
[25] Ahmed N,Brawley VS,Hegde M,et al.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma[J].J Clin Oncol,2015,33 (15): 1688-1696.
[26] Feng K,Guo Y,Dai H,et al.Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J].Sci China Life Sci,2016,59 (5): 468-479.
[27] Newick K,O'Brien S,Moon E,et al.CAR T Cell Therapy for Solid Tumors[J].Annu Rev Med,2017,68:139-152.
[28] Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124 (2): 188-195.
[29] Maude SL,Barrett D,Teachey DT,et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J].Cancer J,2014,20 (2): 119-122.
[30] Lamers CH,Sleijfer S,Vulto AG,et al.Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience[J].J Clin Oncol,2006,24 (13): e20-22.
[31] Lamers CH,Sleijfer S,van Steenbergen S,et al.Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity[J].Mol Ther,2013,21 (4): 904-912.
[32] Parkhurst MR,Yang JC,Langan RC,et al.T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis[J].Mol Ther,2011,19 (3): 620-626.
[33] Kobold S,Grassmann S,Chaloupka M,et al.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy[J].J Natl Cancer Inst,2015,107(8):146.
[34] Wilkie S,van Schalkwyk MC,Hobbs S,et al.Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling[J].J Clin Immunol,2012,32 (5): 1059-1070.
[35] Chen F,Teachey DT,Pequignot E,et al.Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy[J].J Immunol Methods,2016,434: 1-8.
[36] Morgan RA,Yang JC,Kitano M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18 (4): 843-851.